Elypta company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Seed VC - II | Alive

Total Raised


Last Raised

$6.75M | 2 yrs ago

About Elypta

Elypta is a molecular diagnostic company focused on preventing cancer mortality by developing a liquid biopsy platform for detection and monitoring of the disease.

Elypta Headquarter Location

Teknikringen 38A

Stockholm, 114 28,


08-520 278 85

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Elypta

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elypta is included in 5 Expert Collections, including Cancer.



3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'


Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Health IT

7,900 items

Elypta Patents

Elypta has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Biotechnology
  • Cancer treatments
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Kidney cancer, Proteins, Biotechnology, Clusters of differentiation


Application Date


Grant Date



Related Topics

Molecular biology, Kidney cancer, Proteins, Biotechnology, Clusters of differentiation



Latest Elypta News

Elypta to present detection of any-stage cancer results at ASCO 2021

Jun 7, 2021

Elypta to present detection of any-stage cancer results at ASCO 2021 2021-06-07 The cancer detection firm Elypta announced today that two abstracts using its novel metabolism-based liquid biopsy will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021. Results highlight that Elypta’s new class of metabolic biomarkers, GAGomes (the full profile of free glycosaminoglycans), can detect a third of all stage I/low-grade tumors across cancer, including for example genitourinary or brain tumors. The validated sensitivity to stage I/low-grade cancers was 31% in plasma and 33% in urine with a false positive rate of 2%. The study, conducted in collaboration with the Chalmers University of Technology, included over 1500 samples across 14 types of cancer, across all stages and healthy controls. “We were curious to see how GAGomes behaved across several types of cancer. So far, we have had data only in renal cell carcinoma. We discovered that several GAGome features in plasma and urine were altered across cancers compared to normal, healthy levels – even in early-stage cancers. This finding remains to be verified in other populations, but the size of this study gives us confidence in the potential of GAGomes as multicancer biomarkers,” says lead researcher Siniša Bratulić from the Division of Systems and Synthetic Biology at the Chalmers University of Technology. “The study points to the benefits of looking beyond genomic and proteomic biomarkers to deliver on the promise of early cancer detection. It appears that about a third of all cancers activate very early on a metabolic program that severely affects the normal level of GAGomes – both in plasma and urine. This is the crucial observation that allowed us to develop a multicancer early detection test as part of this study. The most exciting aspect is that this test seems to detect cancer types with few good options for early diagnoses, like brain tumors, and critically, at a stage when treatment is likely to result in better outcomes for patients,” says Elypta CSO and co-founder Francesco Gatto. “We are now working to pilot our test in prospective studies for multicancer early detection”. Another study to be presented at ASCO shows the performance of GAGomes to predict and monitor response to treatment in metastatic renal cell carcinoma. No liquid biomarkers are approved for this use today. The following are details of the abstract sessions, which are also available at www.asco.org Detection of any-stage cancer using plasma and urine glycosaminoglycans. Abstract #3034. Poster Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Plasma and urine free glycosaminoglycans as monitoring and predictive biomarkers in metastatic renal cell carcinoma: A prospective observational study. Abstract #e16540 . Publication only track: Genitourinary Cancer—Kidney and Bladder Related companies

Elypta Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Elypta Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.